# CJC-1295 (no DAC) Peptide

> CJC-1295 no DAC is a short-acting Modified GRF 1-29 analog that stimulates pituitary GH pulses without the albumin-binding DAC tail.

Canonical: https://pepflow.app/peptides/cjc-1295-no-dac/

The Pulse Signal

A short-acting Modified GRF 1-29-style GHRH analog that lacks the DAC albumin-binding tail, best understood as a pulse-oriented GH-axis signal rather than the long-acting CJC-1295 form.

GH pulse  Body composition  Sleep  Recovery

Tier B

Evidence Emerging

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 22 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is CJC-1295 (no DAC)?

CJC-1295 without DAC is the common wellness-market name for Modified GRF 1-29, a modified version of the active 1-29 region of growth-hormone-releasing hormone. The practical identity point is simple: it is a GHRH analog, not growth hormone itself.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

The no-DAC distinction matters because the molecule does not carry the albumin-binding tail. CJC-1295 was engineered to stay in circulation much longer through albumin binding; no-DAC Modified GRF 1-29 is discussed as the shorter-acting, pulse-oriented member of the same GHRH-analog family.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

The biological idea is upstream signaling. GHRH fragments and D-Ala2 analogs can stimulate pituitary GH release in normal men, and older GHRH(1-29) studies show GH and IGF-1 movement after repeated subcutaneous dosing.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

The naming needs precision. CJC-1295, CJC-1295 without DAC, sermorelin, tesamorelin, and CJC-1295 plus ipamorelin blends are related GH-axis topics, but they do not share the same duration, dosing logic, evidence package, or safety review.[\[18\]](<https://www.fda.gov/media/183819/download>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/>) For more context, read the [CJC-1295 DAC and no-DAC comparison](<https://pepflow.app/blog/cjc-1295-dac-vs-no-dac/>).

## What CJC-1295 (no DAC) is investigated for

CJC-1295 (no DAC) evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### GH pulse and IGF-1 biomarker support Injectable 50% Emerging

This is the strongest no-DAC claim: short-acting GHRH-fragment evidence supports GH-axis signaling, while direct no-DAC outcome evidence remains limited.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

#### Human evidence

Human GHRH(1-29) and D-Ala2 analog studies show pituitary GH response, lower metabolic clearance for the D-Ala2 analog, and repeated-dose GH/IGF-1 movement in older men. That supports the short-acting GHRH-fragment rationale but is not a dedicated no-DAC CJC-1295 clinical program.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

#### Animal / mechanistic evidence

The CJC-1295 comparator literature shows how albumin binding creates a different long-acting exposure profile. That contrast is the main mechanistic reason to separate no-DAC Modified GRF 1-29 from albumin-binding CJC-1295.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

### ### Lean-mass and fat-loss outcomes Injectable 45% Preliminary

Lean-mass and fat-loss improvement is commonly discussed for no-DAC CJC-1295, but it should read as an indirect GH-axis hypothesis rather than a proven result.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

#### Human evidence

Older human GHRH(1-29) studies measured GH/IGF-1, strength, DEXA, and metabolic variables, but they do not establish no-DAC CJC-1295 as a lean-mass or fat-loss treatment. Direct no-DAC fat-loss, lean-mass, or waist-outcome trials are missing.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)

#### Animal / mechanistic evidence

The rationale comes from GH/IGF-1 biology and GHRH-axis signaling, not from no-DAC animal models showing lean-mass or fat-loss improvements in healthy adults.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)

### ### Sleep quality Injectable 18% Insufficient

Sleep quality is a common no-DAC CJC-1295 tracking claim, but the evidence supports GH-axis timing physiology more than sleep endpoints.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)

#### Human evidence

Nightly GHRH(1-29) studies measured nocturnal GH physiology, and bedtime timing is common in GH-oriented schedules. Those studies do not prove no-DAC CJC-1295 improves sleep quality, sleep stages, or insomnia symptoms.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

#### Animal / mechanistic evidence

The mechanism is timing and GH physiology rather than a direct sleep pathway. Evidence should not turn overnight GH rhythm into a sleep-quality claim without sleep endpoints.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

### ### Recovery support Injectable 16% Insufficient

Recovery support is commonly discussed with no-DAC CJC-1295, but it should be shown as an indirect GH-axis claim until recovery-specific human evidence exists.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42160466/>)

#### Human evidence

Controlled no-DAC CJC-1295 human evidence does not show faster exercise recovery, injury recovery, soreness reduction, strength gain, or training adaptation. Sports-medicine reviews keep unapproved peptide performance claims separate from proven outcomes.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42160466/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/41476424/>)

#### Animal / mechanistic evidence

Mechanistic support is limited to GH-axis plausibility and GHRH analog pharmacology. It does not replace recovery-specific human endpoints.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

## Evidence snapshot

### Overall confidence

Emerging

60%

No-DAC CJC-1295 has a plausible GH-axis rationale and adjacent human GHRH evidence, but less direct evidence than CJC-1295. The cleanest conclusion is pulse-oriented GH-axis signaling with weak direct proof for body-composition, sleep, or recovery outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

50%

### Human evidence

Emerging

Human evidence supports GHRH(1-29) and D-Ala2 analog GH signaling, plus older repeated-dose GHRH(1-29) biomarker movement. Dedicated no-DAC CJC-1295 outcome trials are not established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

40%

### Animal / preclinical

Limited

Preclinical and analytical support mainly clarifies the GHRH-analog family and the DAC distinction. The no-DAC page should not borrow DAC mouse or rat outcomes as human no-DAC benefits.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/30489688/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/34665524/>)

60%

### Mechanism support

Moderate

Mechanism support is stronger than outcome support: no-DAC Modified GRF 1-29 is a GHRH-fragment analog, D-Ala2 modification reduces clearance, and the lack of DAC separates it from albumin-binding CJC-1295.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)

## Forms & administration

CJC-1295 no DAC is primarily discussed as a subcutaneous, short-acting GHRH analog. Route, DAC status, timing, product identity, and whether it is paired with a GHRP change how the schedule should be interpreted.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 100-200 mcg per dose.

### Frequency

Usually taken 1-3 times daily.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

### Timing Considerations

Common timing is morning, after a workout, or before bed.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)

### Cycle Length

Common cycles run 8-12 weeks.

[Full CJC-1295 (no DAC) dosage guide](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/>)

## What to expect

### Same day

Upstream GH-axis pulse, with practical notes around appetite, sleep timing, warmth or flushing, and recovery feel against normal baseline.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### First 1-2 weeks

Early GH and IGF-1 biomarker movement in responsive older men, alongside sleep quality, recovery feel, appetite, water retention, and day-to-day training tolerance.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

### Weeks 4-8

Steadier lab movement, sleep and recovery patterns, body-composition trend, training tolerance, and metabolic measures across the protocol block.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)

### After stopping

Quick fade of the short-acting GH pulse, with slower settling of IGF-1 labs, weight trend, sleep, and training markers.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

## Safety profile

CJC-1295 no DAC should be treated as endocrine-active and route-specific. Human GHRH-fragment studies are small or adjacent, while FDA flags CJC-1295 compounding concerns involving immunogenicity, peptide impurities, API characterization, increased heart rate, systemic vasodilatory reaction, and limited clinical data.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>)

### Common side effects

- Injection-site pain or swelling [\[18\]](<https://www.fda.gov/media/183819/download>)
- Flushing or warmth [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Headache [\[18\]](<https://www.fda.gov/media/183819/download>)
- Dizziness [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Low blood pressure [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Faster heart rate [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Cautions

- Endocrine medical supervision[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)
- Unapproved product quality[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>)
- Prohibited in sport

### What we don't know

Decision-changing unknowns include long-term safety, no-DAC versus DAC risk differences, combination-level safety with GHRPs, repeated non-study use, product identity, special-population safety, and whether downstream outcomes justify endocrine exposure.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Who CJC-1295 (no DAC) is not for

Route-specific avoid and medical-review notes:

- **Competitive athletes**

  Competitive athletes should avoid CJC-1295 no DAC unless their anti-doping authority provides route-specific written clearance. WADA prohibits GHRH and analogs including CJC-1295.
- **Endocrine disease or glucose dysregulation**

  Medical review is needed in endocrine disease, diabetes, insulin resistance, or abnormal GH/IGF-1-related labs because no-DAC CJC-1295 acts through the GH/IGF-1 axis.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)
- **Cancer or growth-factor-sensitive conditions**

  This is a medical-review caution rather than a documented no-DAC cancer-outcome finding. GH/IGF-1 biomarker movement should not be handled through self-directed use in growth-factor-sensitive histories.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- **Pregnancy, breastfeeding, or pediatric use**

  Pregnancy, breastfeeding, and pediatric use are not supported by route-specific no-DAC CJC-1295 safety data.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Other GH-axis drugs or secretagogues**

  This is a theoretical additive-exposure caution. Combining no-DAC CJC-1295 with GH, GHRPs, ipamorelin, CJC-1295, sermorelin, tesamorelin, or other GH-axis agents can make GH/IGF-1 exposure and side-effect interpretation harder to manage.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- **Glucose-active medications**

  This is a theoretical endocrine-monitoring caution. GH/IGF-1 signaling intersects with metabolic regulation, so insulin, diabetes drugs, or weight-management medications need clinician review.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

## Pairing notes

### Commonly included in these stacks

[**GH Stack** GH Stack pairs CJC-1295 no DAC with Ipamorelin. It combines a short-acting GHRH-side analog with Ipamorelin's ghrelin/GHS-receptor signal to organize discrete GH-release windows. CJC-1295 (no DAC) Ipamorelin](<https://pepflow.app/stacks/cjc-1295-no-dac-ipamorelin/>)

### Not recommended with

**Somatropin: compounded GH/IGF-1 effects** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[20\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**CJC-1295: overlapping GHRH signaling** Injectable

CJC variants provide different exposure profiles but stimulate the same GHRH receptor pathway. Combining them duplicates GH/IGF-1 stimulation and makes exposure and monitoring harder to interpret.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

**Sermorelin: overlapping GHRH signaling** Injectable

Sermorelin and CJC-1295 No DAC are closely related GHRH-receptor approaches. Using both duplicates growth-hormone release signaling without a validated combined regimen.[\[21\]](<https://pubmed.ncbi.nlm.nih.gov/8772599/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[22\]](<https://www.fda.gov/media/94155/download>)

### Related peptides

[CJC-1295](<https://pepflow.app/peptides/cjc-1295/>)

## Regulatory status

### United States

United States: not FDA-approved for human use as a drug. No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA query, and FDA CJC-1295-related compounding materials distinguish DAC and non-DAC forms.[\[19\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22Modified%20GRF%201-29%22+OR+products.active_ingredients.name:%22Modified%20GRF%201-29%22+OR+openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>) [\[18\]](<https://www.fda.gov/media/183819/download>) [\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA Drugs@FDA query.[\[19\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22Modified%20GRF%201-29%22+OR+products.active_ingredients.name:%22Modified%20GRF%201-29%22+OR+openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>) | Flagged · FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with potential safety risks, and the PCAC review distinguishes CJC-1295-related substances including DAC and non-DAC forms.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>) |

### Injectable

FDA drug approval

Not Approved

No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA Drugs@FDA query.[\[19\]](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22Modified%20GRF%201-29%22+OR+products.active_ingredients.name:%22Modified%20GRF%201-29%22+OR+openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>)

503A compounding

Flagged

FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with potential safety risks, and the PCAC review distinguishes CJC-1295-related substances including DAC and non-DAC forms.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[18\]](<https://www.fda.gov/media/183819/download>)

### International

International status is route-, product-, and claim-specific. No country-specific therapeutic approval outside the United States is established in this review.

### Sports & competition

Sports competition: prohibited under WADA S2 growth hormone releasing factors. The prohibition covers GHRH and analogs including CJC-1295, regardless of no-DAC labeling.

## How it works

The starting point is natural GHRH. The active 1-29 region can stimulate pituitary somatotroph cells to release GH, and human bolus data show both native GHRH(1-29)-NH2 and a D-Ala2 analog can produce GH responses.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>)

The D-Ala2 modification helps explain why Modified GRF 1-29 exists as a research-market concept. In normal men, D-Ala2 GHRH(1-29) showed lower metabolic clearance and a longer disappearance half-time than native GHRH(1-29)-NH2.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

The no-DAC form lacks the albumin-binding extension that defines CJC-1295. The long-acting form was designed around albumin binding and multi-day exposure, so it should not be used as a drop-in schedule model for no-DAC Modified GRF 1-29.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

The translation limit is downstream outcomes. A GH pulse and IGF-1 movement can be biologically meaningful, but they do not automatically prove better sleep, faster recovery, fat loss, muscle gain, cognition, or vitality.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Research gaps & open questions

What the current literature has not yet settled about CJC-1295 (no DAC):

01

Trials in people need to study the no-DAC form itself. Evidence from related growth-hormone-releasing compounds or the longer-acting DAC form cannot establish its effects.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

02

Controlled trials still need to show whether the no-DAC form actually improves fat loss, lean mass, sleep, recovery, training response, or day-to-day wellbeing.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42160466/>)

03

Direct comparisons between no-DAC and DAC forms should test whether their different duration and growth-hormone-release patterns lead to different benefits or long-term risks.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

04

CJC-1295 no DAC and ipamorelin or other growth-hormone-releasing peptides need to be studied as combinations, including dose, monitoring, side effects, and anti-doping risk.

## Common questions

### What is the difference between CJC-1295 and no DAC?

CJC-1295 has an albumin-binding extension designed for long duration. No-DAC CJC-1295 is usually Modified GRF 1-29, a shorter-acting GHRH analog used around pulse timing rather than multi-day exposure.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

### What is CJC-1295 no DAC investigated for?

It is mainly discussed for GH pulse and IGF-1 biomarker support, body-composition improvements, sleep quality, and recovery support. The strongest support is GH-axis signaling; the downstream results remain weak.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)

### What is the CJC-1295 no DAC dose?

Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose, 1-3 times daily, with morning, post-workout, or before-bed timing.

### Can CJC-1295 no DAC be combined with ipamorelin?

No-DAC CJC-1295 and ipamorelin are a common GH-axis stack candidate because they act through different signaling pathways. Combination-level efficacy, safety, dosing, monitoring, and sports status still need separate review before the pair is treated as recommended.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

### Is CJC-1295 no DAC allowed in sport?

No for WADA-governed sport. WADA prohibits growth hormone releasing factors, including GHRH analogs such as CJC-1295, at all times.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/34665524/>)

## Myths & misconceptions

### Myth

No-DAC CJC-1295 is just faster CJC-1295.

### Reality

They should be treated as different pharmacology problems. DAC adds albumin-binding chemistry and multi-day exposure; no-DAC Modified GRF 1-29 lacks that extension and is scheduled around short pulses.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

### Myth

Pulse-oriented dosing proves no-DAC is safer.

### Reality

Shorter exposure may change the risk profile, but it does not prove long-term safety. Both forms act through GH/IGF-1 biology, and CJC-1295-related products still carry product-quality and endocrine-monitoring concerns.[\[17\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)

### Myth

CJC-1295 no DAC plus ipamorelin is a proven recovery stack.

### Reality

The pair is common and mechanistically coherent, but combination-level outcome, safety, dose, timing, and anti-doping evidence need their own review.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## History & discovery

No-DAC CJC-1295 sits at the intersection of older GHRH(1-29) pharmacology, D-Ala2 analog work, and later CJC-1295 development. Its public use pattern grew from a naming shortcut for Modified GRF 1-29, not from a dedicated no-DAC approval program.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

A human study found GHRH(1-29)-NH2 and a D-Ala2 analog stimulated GH release in normal men, with the D-Ala2 analog showing greater potency.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>)

Older-men studies examined repeated GHRH(1-29) dosing, while a D-Ala2 GHRH(1-29) pharmacokinetic study found lower clearance than native GHRH(1-29).[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/1379256/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)

CJC-1295 was identified as a long-lasting albumin-binding GHRH analog and then studied in healthy adults for multi-day GH and IGF-1 biomarker response.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/15817669/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)

Analytical and sports-medicine literature discusses modified GRF and GHRH analogs in doping and unapproved peptide settings, while FDA materials continue to distinguish CJC-1295-related forms for compounding review.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/30136411/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/34665524/>) [\[18\]](<https://www.fda.gov/media/183819/download>)

## Published research 22 citations

- [\[1\] **Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.** PubMed / Peptides, 1985. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/2866496/>)
- [\[2\] **Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.** PubMed / Journal of Clinical Endocrinology and Metabolism, 1994. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)
- [\[3\] **Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.** PubMed / Journal of Clinical Endocrinology and Metabolism, 1992. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)
- [\[4\] **Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.** PubMed / Metabolism, 1997. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)
- [\[5\] **Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.** PubMed Central / Archives of Neurology, 2012. human clinical.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/>)
- [\[6\] **Growth hormone releasing hormone improves the cognition of healthy older adults.** PubMed / Neurobiology of Aging, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16399214/>)
- [\[7\] **Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.** PubMed / Endocrinology, 2005. animal.](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)
- [\[8\] **Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)
- [\[9\] **Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)
- [\[10\] **Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.** PubMed Central / Growth Hormone & IGF Research, 2009. human clinical.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/>)
- [\[11\] **Glycine-modified growth hormone secretagogues identified in seized doping material.** PubMed / Drug Testing and Analysis, 2019. regulatory.](<https://pubmed.ncbi.nlm.nih.gov/30136411/>)
- [\[12\] **Advances in the detection of growth hormone releasing hormone synthetic analogs.** PubMed / Drug Testing and Analysis, 2021. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/34665524/>)
- [\[13\] **An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.** PubMed / Drug Testing and Analysis, 2019. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/30489688/>)
- [\[14\] **Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.** PubMed / Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- [\[15\] **Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.** PubMed / JBJS Reviews, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/42160466/>)
- [\[16\] **Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.** PubMed / American Journal of Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41476424/>)
- [\[17\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[18\] **FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/media/183819/download>)
- [\[19\] **openFDA Drugs@FDA query for CJC-1295 no-DAC and Modified GRF 1-29** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name:%22Modified%20GRF%201-29%22+OR+products.active_ingredients.name:%22Modified%20GRF%201-29%22+OR+openfda.substance_name:%22CJC-1295%22+OR+products.active_ingredients.name:%22CJC-1295%22&limit=1>)
- [\[20\] **NORDITROPIN somatropin injection prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)
- [\[21\] **Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.** The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8772599/>)
- [\[22\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/media/94155/download>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

B

**Evidence**

60% Emerging

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[22 citations](<https://pepflow.app/peptides/cjc-1295-no-dac/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- GH pulse and IGF-1 biomarker support
- Lean-mass and fat-loss outcomes
- Sleep quality
- Recovery support

### Common side effects

- Injection-site pain or swelling
- Flushing or warmth
- Headache

### Also known as

- CJC-1295 without DAC
- Modified GRF 1-29
- Mod GRF 1-29
- Tetrasubstituted GRF 1-29

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [CJC 1295 DAC vs No DAC: Make Your Choice](<https://pepflow.app/blog/cjc-1295-dac-vs-no-dac/>)
- [CJC-1295 (no DAC) dosage guide](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/>)
- [GH Stack](<https://pepflow.app/stacks/cjc-1295-no-dac-ipamorelin/>)
